Nebivolol and Weight Neutrality
Key Evidence Supporting Weight Neutrality
- The American Heart Association and American College of Cardiology recommend avoiding traditional beta-blockers as first-line treatment in overweight or obese patients due to weight gain concerns, and instead suggest selecting nebivolol or carvedilol when beta-blockers are medically required 1, 2, 3
- The Gastroenterology guidelines state that selective beta-blockers with a vasodilating component, such as nebivolol, have less potential for weight gain and minimally affect lipid and glucose metabolism 1, 2
Clinical Recommendation Algorithm
- For patients with weight concerns requiring antihypertensive therapy, the American College of Cardiology recommends first-line options such as ACE inhibitors, ARBs, or calcium channel blockers, which are weight-neutral 3, 4
- If a beta-blocker is required, the American College of Cardiology recommends choosing nebivolol or carvedilol over traditional beta-blockers such as atenolol, metoprolol, or propranolol 1, 2, 3